Recent News

 

June 9, 2021

 

Oncology Pharma and Ribera Solutions Release White Paper Regarding Patient Engagement and Retention Platfomr

 

 

May 18, 2021

 

Oncology Pharma, Inc. Is Pursuing the Development of its Small Molecule Drug for the Treatment of Colon Cancer

 

 

May 7, 2021

Oncology Pharma Enters into License Agreement for Small Molecules Intellectual Property for the Treatment of Colon Cancer

April 21, 2021

Oncology Pharma, Inc. Prepares Plan Toward Funding Development and Implementation of Ribera Solutions' Patient Engagement and Retention Platform

 

April 14, 2021

 

Oncology Pharma, Inc. Addresses Pancreatic Cancer, the Need for an Effective Therapy and the Potential of mRNA Technology

 

April 7, 2021

 

Oncology Pharma Signs License Agreement for mRNA Intellectual Property As It Reveals Strategic Plans for Treating Pancreatic Cancer

 

March 31, 2021

 

Oncology Pharma Has Provided Initial Funding to NanoSmart Pharmaceuticals to Conduct Feasibility Studies for Initial Phases of IND-Enabling Activities

 

March 16, 2021

 

Oncology Pharma Reveals Strategic Plans for Company Growth and Focus

 

March 10, 2021

 

Oncology Pharma, Inc. Vetting CROs to Develop Research Plan and Indications for Recently Licensed Cancer Combination Therapy

 

March 4, 2021

 

Oncology Pharma Moves to Fund Lead Drug Formulation & IND-Enabling Studies

 

 

February 26, 2021

Oncology Pharma Signs Worldwide Licensing Agreement with Sybleu, Inc. for Commercialization of Chemotherapeutic Agent in Combination with a Bioactive Immunostimulatory Agent

February 22, 2021

Oncology Pharma Extends Licensing Agreement with NanoSmart Pharmaceuticals, Inc. for Veterinary Oncology

February 16, 2021

Oncology Pharma is Pleased to Welcome New Chairman to its Scientific Advisory Board

 

February 9, 2021

Oncology Pharma Renews Licensing Agreement with Ribera Solutions LLC for its Connect2Med Clinical Trials Platform

 

 

February 3, 2021

Oncology Pharma Extends its Licensing Agreement with NanoSmart Pharmaceuticals, Inc. for Human Oncology

January 28, 2021

Oncology Pharma Announces the Appointment of New Chief Financial Officer

 

August 27, 2020

Oncology Pharma Announces Extension of Letter of Intent with Kalos Therapeutics, Retained an Interim CEO and Approval of Reverse Stock Split

 

 

April 21, 2020

Oncology Pharma Licensor and Co-Development Partner, Kalos Therapeutics, Announces Progress in Covid-19 Preventative & Therapeutic Approaches

April 6, 2020

Oncology Pharma and Kalos Therapeutics Expand Licensing Agreement for Exploring Kalos's Anti-Cancer Lead Drug in Treating COVID-19

March 11, 2020

 

Oncology Pharma Continues Licensing Agreement with NanoSmart

 

 

January 28, 2020

Oncology Pharma, Inc. Narrows Focus on Funding Efforts

2019

 

December 26, 2019

Oncology Pharma Receives LOI for Financing for US$ 38.4M from SCP Investment Partners, Ltd.